Compare SNDX & PLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | PLAB |
|---|---|---|
| Founded | 2005 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2016 | 1987 |
| Metric | SNDX | PLAB |
|---|---|---|
| Price | $21.21 | $33.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 2 |
| Target Price | $36.92 | ★ $43.50 |
| AVG Volume (30 Days) | 1.6M | ★ 2.1M |
| Earning Date | 11-03-2025 | 12-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.09 |
| EPS | N/A | ★ 2.28 |
| Revenue | $111,304,000.00 | ★ $849,294,000.00 |
| Revenue This Year | $620.14 | $7.61 |
| Revenue Next Year | $115.42 | $7.50 |
| P/E Ratio | ★ N/A | $14.79 |
| Revenue Growth | ★ 595.65 | N/A |
| 52 Week Low | $8.58 | $16.46 |
| 52 Week High | $22.73 | $39.80 |
| Indicator | SNDX | PLAB |
|---|---|---|
| Relative Strength Index (RSI) | 64.62 | 64.43 |
| Support Level | $19.72 | $33.11 |
| Resistance Level | $22.73 | $34.66 |
| Average True Range (ATR) | 0.91 | 2.00 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 59.94 | 61.50 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.